Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 10, 2023

SELL
$29.0 - $38.37 $893,606 - $1.18 Million
-30,814 Reduced 72.43%
11,732 $441,000
Q1 2023

May 11, 2023

BUY
$23.85 - $31.34 $665,963 - $875,106
27,923 Added 190.95%
42,546 $1.25 Million
Q4 2022

Feb 13, 2023

BUY
$17.65 - $27.37 $96,368 - $149,440
5,460 Added 59.59%
14,623 $385,000
Q3 2022

Nov 10, 2022

BUY
$22.62 - $32.54 $207,267 - $298,164
9,163 New
9,163 $213,000
Q3 2021

Nov 15, 2021

SELL
$46.35 - $59.75 $391,518 - $504,708
-8,447 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$47.2 - $67.81 $398,698 - $572,791
8,447 New
8,447 $443,000
Q4 2020

Feb 16, 2021

SELL
$18.53 - $31.5 $488,043 - $829,647
-26,338 Closed
0 $0
Q3 2020

Nov 16, 2020

BUY
$14.68 - $19.12 $386,641 - $503,582
26,338 New
26,338 $488,000

Others Institutions Holding VCEL

About Vericel Corp


  • Ticker VCEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 47,178,000
  • Market Cap $2.34B
  • Description
  • Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for t...
More about VCEL
Track This Portfolio

Track Exodus Point Capital Management, LP Portfolio

Follow Exodus Point Capital Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Exodus Point Capital Management, LP with notifications on news.